Trial Outcomes & Findings for Effects of Transcranial Pulse Stimulation in Parkinson's Disease (NCT NCT06676995)

NCT ID: NCT06676995

Last Updated: 2026-08-10

Results Overview

Unified Parkinson's Disease Rating Scale (UPDRS) evaluates the motor function, non-motor symptoms (mentation, behavior, and mood), activities of daily living, and complications of therapy. Each item has 0-4 ratings: 0 (normal), 1 (slight), 2 (mild), 3 (moderate), and 4 (severe). The total UPDRS score is obtained by summing Parts I-IV, with a total score ranging from 0 to 199. Lower scores indicate less severe Parkinson's disease and represent a better outcome; higher scores indicate greater disease severity and represent a worse outcome. The outcome measure represents the change from Baseline to 4 weeks, immediately post-intervention (Visit 12).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

14 participants

Primary outcome timeframe

Baseline and 4 weeks, immediately post-intervention (Visit 12).

Results posted on

2026-08-10

Participant Flow

Participant milestones

Participant milestones
Measure
Active TPS
The treatment protocol consisted of 12 Transcranial Pulse Stimulation (TPS) sessions administered over 4 weeks (3 sessions per week). Each session lasted approximately 50 min and involved administering 10,000 individual pulses. 8000 pulses were delivered to the brain at an energy flux density of 0.25 millijoule/millimeter (mJ/mm)2 with a repetition rate of 4 Hz and a penetration depth up to 8 cm, sufficient to modulate cortical and subcortical structures, and 2000 pulses at an energy flux density of 0.10 mJ/mm2 and 4 Hz were provided on the foot soles.
Overall Study
STARTED
14
Overall Study
COMPLETED
14
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Effects of Transcranial Pulse Stimulation in Parkinson's Disease

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Active TPS
n=14 Participants
The treatment protocol consisted of 12 TPS sessions administered over 4 weeks (3 sessions per week). Each session lasted approximately 50 min and involved administering 10,000 individual pulses. 8000 pulses were delivered to the brain at an energy flux density of 0.25 Millijoule/millimeter2 with a repetition rate of 4 hertz and a penetration depth up to 8 cm, sufficient to modulate cortical and subcortical structures, and 2000 pulses at an energy flux density of 0.10 Millijoule/millimeter2 and 4 hertz were provided on the foot soles.
Age, Continuous
69.36 years
STANDARD_DEVIATION 8.53 • n=54 Participants
Sex: Female, Male
Female
4 Participants
n=54 Participants
Sex: Female, Male
Male
10 Participants
n=54 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=54 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
13 Participants
n=54 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=54 Participants
Region of Enrollment
United States
14 participants
n=54 Participants
Unified Parkinson's Disease Rating Scale (UPDRS)
47.79 units on a scale
STANDARD_DEVIATION 16.56 • n=54 Participants

PRIMARY outcome

Timeframe: Baseline and 4 weeks, immediately post-intervention (Visit 12).

Unified Parkinson's Disease Rating Scale (UPDRS) evaluates the motor function, non-motor symptoms (mentation, behavior, and mood), activities of daily living, and complications of therapy. Each item has 0-4 ratings: 0 (normal), 1 (slight), 2 (mild), 3 (moderate), and 4 (severe). The total UPDRS score is obtained by summing Parts I-IV, with a total score ranging from 0 to 199. Lower scores indicate less severe Parkinson's disease and represent a better outcome; higher scores indicate greater disease severity and represent a worse outcome. The outcome measure represents the change from Baseline to 4 weeks, immediately post-intervention (Visit 12).

Outcome measures

Outcome measures
Measure
Active TPS
n=14 Participants
The treatment protocol consisted of 12 TPS sessions administered over 4 weeks (3 sessions per week). Each session lasted approximately 50 min and involved administering 10,000 individual pulses. 8000 pulses were delivered to the brain at an energy flux density of 0.25 mJ/mm2 with a repetition rate of 4 Hz and a penetration depth up to 8 cm, sufficient to modulate cortical and subcortical structures, and 2000 pulses at an energy flux density of 0.10 mJ/mm2 and 4 Hz were provided on the foot soles.
Unified Parkinson's Disease Rating Scale (UPDRS)
-9.43 units on a scale
Standard Deviation 5.36

Adverse Events

Active TPS

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Active TPS
n=14 participants at risk
The treatment protocol consisted of 12 TPS sessions administered over 4 weeks (3 sessions per week). Each session lasted approximately 50 min and involved administering 10,000 individual pulses. 8000 pulses were delivered to the brain at an energy flux density of 0.25 mJ/mm2 with a repetition rate of 4 Hz and a penetration depth up to 8 cm, sufficient to modulate cortical and subcortical structures, and 2000 pulses at an energy flux density of 0.10 mJ/mm2 and 4 Hz were provided on the foot soles.
Skin and subcutaneous tissue disorders
Mild pain/pressure
14.3%
2/14 • Number of events 2 • 4 weeks
Adverse events were collected using an adverse events questionnaire.

Additional Information

Dr. Felipe Fregni

Spaulding Rehabilitation Hospital, Inc.

Phone: 6179526158

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place